Can-Fite BioPharma | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome	Abnormalities, Multiple, Amino Acid Transport Disorders, Inborn, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Urogenital Diseases, X-linked disease, brain disorder, central nervous system disorder, hereditary disease, inborn errors of metabolism, kidney disorder, metabolic disease, nervous system disorder, oculocerebrorenal syndrome, renal tubular transport disease, urinary system disorder	Not yet recruiting	Phase 2	2026-02-18		NCT07410455
A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy	Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorder	Not yet recruiting	Phase 3	2025-04-29		NCT06643260
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis	Digestive System Diseases, Digestive System Neoplasms, Fibrosis, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, cirrhosis of liver, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm	Recruiting	Phase 3	2025-04-29		NCT05201404
Namodenoson Treatment of Advanced Pancreatic Cancer	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic adenocarcinoma, pancreatic neoplasm	Recruiting	Phase 2	2025-01-31		NCT06387342